<DOC>
	<DOCNO>NCT01229332</DOCNO>
	<brief_summary>A cross-over study , ND0611 placebo test top 3 different LD/CD dosage form . Safety tolerability , pharmacokinetic profile levodopa carbidopa potential clinical effect ND0611 explore subject PD motor fluctuation .</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacokinetic Study ND0611 Top Different Oral Dosage Forms Levodopa/Carbidopa Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Men woman idiopathic Parkinson 's disease 2 . Subjects must experience motor fluctuation associate LD/CD dose 3 . Modified Hoehn Yahr stage &lt; 5 4 . Subjects must take optimized stable levodopa/dopa decarboxylase inhibitor therapy 5 . Women must postmenopausal , surgically sterilize , use adequate birth control . Women childbearing potential must negative pregnancy test ( serum betaHCG ) screening . 6 . Subjects must age 30 old . 7 . Subjects must willing able give inform consent . 1 . Subjects clinically significant unstable medical surgical condition 2 . Subjects clinically significant psychiatric illness . 3 . Premenopausal woman , use birth control method . 4 . Subjects take experimental medication within 60 day prior baseline . 5 . Subject undergone neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , transplantation deep brain stimulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Motor fluctuation levodopa pharmacokinetics carbidopa solution continuous</keyword>
</DOC>